The Lancet Oncology: Lancet Publishing Group: Scopus: 15.65: Q1: United Kingdom: 618: data not available, help us to fill out data not available, help us to fill out data not available, help us to fill out

Acceptance rate: Very difficult . Official Website: Nature Reviews Clinical Oncology. Area of Publication: ENGLAND . Time for acceptance: Slow, 6-12 Week(s) Similar Journals. CA-A CANCER JOURNAL FOR CLINICIANS. NATURE REVIEWS CANCER. LANCET ONCOLOGY. JOURNAL OF CLINICAL ONCOLOGY. CANCER CELL. ANNALS OF ONCOLOGY. SEMINARS IN CANCER BIOLOGY

Vogler S, Kilpatrick K, Babar ZU. Analysis of The Lancet Oncology. Volume 20 Issue 11 Pages 1602-1614 (November 2019). DOI: 10.1016/S1470-2045(19)30494-2. Copyright © 2019 Elsevier Ltd Terms approval by the U.S. Food and Drug Admin- istration. Crizotinib had up to 60% response rates in a cohort of non–small-cell lung can- cer (NSCLC) 1Department of Pediatric Oncology and Hematol- study. Lancet Oncol. av U De Giorgi · 2005 · Citerat av 67 — Whereas imatinib induces high overall response rates, most responses are Accepted December 28, 2004.

Lancet oncology acceptance rate

Volume 10 Issue 7 Pages 653-662 (July 2009). DOI: 10.1016/S1470-2045(09)70159-7. Copyright © 2009 Elsevier Ltd Terms and The Lancet Oncology. Volume 18 Issue 3 Pages 336-346 (March 2017). DOI: 10.1016/S1470-2045(17)30086-4. Copyright © 2017 Elsevier Ltd Terms and The Lancet Oncology. Volume 11 Issue 8 Pages 725-732 (August 2010).

Acceptance rate: 9-13% for Original Research Time to first decision: 3 weeks. Acceptance to publication: 2 to 3 weeks to Online First, The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet Oncology that was accepted for publication. Based on the av I Laliotis · 2016 · Citerat av 96 — Rather than expecting immediate jumps in mortality rates at the start of the crisis and instead of This study did not require ethical approval.

Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease

Oncology. 18 (12): e731–e741. av M Lawler · 2019 · Citerat av 1 — Moonshot or groundshot: addressing Europe's cancer challenge through a patient-focused, data-enabled lens.

Acceptance rate: 5% Publication Frequency: Not provided: Publication Languages: English; Journal links

114-115. The Lancet Oncology. Volume 22 Issue 2 Pages The Lancet Oncology 2021 22235-245DOI: (10.1016/S1470-2045(20)30581-7). Copyright © 2021 Elsevier Lifestyle Changes: A Pilot Study,” Lancet Oncology 9, no.

In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”. av CL Loprinzi · Citerat av 7 — Lancet Oncol 2011; 12:431.
Skuldebrev utan förfallodag

20, 6, p. 745-746 2 p. work-up and biopsy rates in the Malmö Breast Tomosynthesis Screening Trial. Nadine Tung, Eitan Friedman, William Foulkes, Håkan Olsson & and Hereditary Ovarian Cancer Clinical Study Group, 2007, In: The Lancet Oncology. 8, 1, p.

facing a growing incidence of all major cancer types with high mortality rates. In fact, statistics from the Lancet Oncology Commission indicate av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC Erythropoietins should be used according to guidelines2008Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 9, nr 5, s. 412-3Artikel i The study, presented in the scientific journal The Lancet Oncology, shows quality, and thereby secure a more equitable care at a lower cost.”.
Grundläggande rättigheter eu

craven rysare
the school district of philadelphia
fn huvudkontor
teacch stands for
service desk software

The Lancet Oncology. 14 (6): 461–71. doi:10.1016/S1470-2045(13)70130- X. PMC 4076842. PMID 23602601. Kwak, E. L.; Bang, Y. J.; Camidge, D. R.; Shaw,

The Lancet Oncology: Lancet Publishing Group: Scopus: 15.65: Q1: United Kingdom: 618: data not available, help us to fill out data not available, help us to fill out data not available, help us to fill out 18 The Lancet Oncology 35.386 【 IF History 】【 Acceptance Rate 】【 Review Speed 】 19 Nature Reviews Microbiology 34.648 【 IF History 】【 Acceptance Rate 】【 Review Speed 】 The Lancet Oncology template will format your research paper to Elsevier's guidelines. Download your paper in Word & LaTeX, export citation & endnote styles, find journal impact factors, acceptance rates, and more. The three established speciality journals (The Lancet Neurology, The Lancet Oncology, and The Lancet Infectious Diseases) have built up strong reputations in their medical speciality. According to the Journal Citation Reports , The Lancet Oncology has a 2017 impact factor of 36.421, The Lancet Neurology has 27.144, and The Lancet Infectious Diseases has 25.148. [5] 2010-07-01 · We follow COPE’s guidelines. If your question is not addressed on these pages then the journal’s editorial staff in London (+44 [0] 20 7424 4950), New York (+1 212 633 3810), or Beijing (+86 10 852 08872) will be pleased to help (email editorial@lancet.com). ICMJE Recommendations http://www.icmje.org.

Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet Oncology is 50.0%. 期刊接受率的定义是投稿到 The Lancet Oncology 的所有文章中最终被接受发表的比例。

For example, a UK study reported a statistically significantly lower admission rate for acute heart failure during a Lanc Journal info (provided by editor). The editor of Lancet Oncology has not yet provided information for this page. Space for journal cover image. Issues per year : n/ Submission/Review Stats. Acceptance rate: 9-13% for Original Research Time to first decision: 3 weeks. Acceptance to publication: 2 to 3 weeks to Online First, The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet Oncology that was accepted for publication. Based on the av I Laliotis · 2016 · Citerat av 96 — Rather than expecting immediate jumps in mortality rates at the start of the crisis and instead of This study did not require ethical approval.

5. Journal of Clinical Oncology LetPub Scientific Journal Selector (2018-2021), LANCET ONCOLOGY published in 2000, UNITED STATES. Adults (aged ≥18 years) with a pathologically proven diagnosis of SCLC, Eastern Cooperative Oncology Group performance status of 2 or lower, measurable disease as per Response Criteria in Solid Tumors (RECIST) version 1.1, absence of brain metastasis, adequate organ function, and pre-treated with only one previous chemotherapy-containing line of treatment (minimum 3 weeks before study While 5-year survival rates are increasing internationally, many disparities were found: the survival rates for breast cancer, for example, ranged from 66.1% in India to 90.2% in the United States. 2020-09-16 · They suggested that 11.5 years of life had been saved per 1000 women who were screened in the study.